# ImageneBio, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/ImageneBio, Inc.). ## Overview ImageneBio, Inc. is a clinical-stage biopharmaceutical company developing immunology and inflammation therapies, with its lead program IMG-007 designed as a non-depleting anti-OX40 monoclonal antibody. The company is focused on advancing IMG-007 for atopic dermatitis and potentially broader autoimmune and inflammatory diseases, while it has also been pursuing strategic alternatives and winding down legacy oncology activities. ## Products & services • IMG-007 anti-OX40 monoclonal antibody for autoimmune/inflammatory disease • Atopic dermatitis clinical development program • Broader immunology and inflammatory disease pipeline • Licensing and collaboration agreements for intellectual property • Research and development services tied to partnered programs - **Clinical-stage therapeutics** (0%) — Drug candidates in preclinical and clinical development, centered on IMG-007 and related immunology programs. - **Licensing revenue** (100%) — Non-refundable upfront payments and other consideration from IP licensing deals. - **Collaboration revenue** (0%) — Revenue from strategic partner arrangements covering research, development, and commercialization rights. - IMG-007 non-depleting anti-OX40 monoclonal antibody - Atopic dermatitis proof-of-concept clinical program - Autoimmune and inflammatory disease indications - Licensing agreements for intellectual property - Collaboration agreements with upfront and milestone economics ## Customers ImageneBio does not yet sell approved products to end patients; its current counterparties are licensing and collaboration partners that pay upfront fees, milestones, and potential royalties. If IMG-007 is commercialized, the end customers would be physicians, hospitals, and payors in dermatology and immunology markets, but today the business is still partner-funded and development-stage. - **Licensing and collaboration partners** (primary) — Companies that pay upfront fees, milestones, and royalties for access to ImageneBio's intellectual property and development programs. - **Clinical trial patients** (primary) — Patients with atopic dermatitis and other inflammatory diseases enrolled to generate proof-of-concept and safety data for IMG-007. - **Future dermatology and immunology prescribers** (emerging) — Specialist physicians who would prescribe IMG-007 if approved, based on efficacy, safety, and dosing convenience. - **Future payors and health systems** (emerging) — Insurers and healthcare systems that would reimburse treatment if the product reaches market and demonstrates value. - Biopharma partners buying IP rights and development access - Collaborators funding research and milestone-based programs - Future dermatology prescribers if IMG-007 is approved - Future payors and health systems in autoimmune care - Clinical trial participants enrolled in IMG-007 studies ## Geography The company is headquartered in San Diego, California and operates as a U.S.-based development-stage biotech. Its business is global in nature through clinical development, manufacturing outsourcing, and potential future partnering, but the disclosed filings do not provide a country revenue split because revenue comes from licensing and collaboration arrangements rather than product sales. - Headquartered in San Diego, California - U.S.-based corporate and R&D operations - Relies on third-party manufacturing, including WuXi Biologics - Clinical and regulatory activity is global in scope - No disclosed country revenue split from product sales ## Strategy The near-term strategy is centered on advancing IMG-007 in atopic dermatitis and potentially additional immunology and inflammatory indications, while preserving capital through strategic alternatives and reduced legacy program spend. The company also depends on partnering and external manufacturing, so execution on collaborations, clinical data, and regulatory milestones is central to its value creation. - **Advance IMG-007 clinical development** (short-term) — Clinical proof-of-concept data is the main driver of valuation and partnering interest. - **Complete strategic alternatives / merger process** (short-term) — The company has been pursuing a transaction to maximize shareholder value and reshape the business. - **Maintain capital efficiency** (short-term) — As a clinical-stage company with no product sales, preserving cash extends runway and reduces dilution risk. - Advance IMG-007 through clinical development - Expand from atopic dermatitis into broader inflammatory indications - Use strategic alternatives to maximize shareholder value - Rely on partnerships to fund development and commercialization - Outsource manufacturing to avoid building internal capacity ## Risks The company faces classic clinical-stage biotech risks: trial failure, regulatory delay, and the need for substantial additional capital before any product revenue can exist. It also has concentrated manufacturing and supply-chain exposure through a single-source supplier, plus transaction risk tied to the proposed merger and strategic alternatives process. - **Clinical development risk for IMG-007** [high] — The lead asset is still in development, so efficacy or safety setbacks could stop the program. - **Need for additional capital** [high] — The company has no product revenue and expects to fund operations through financing or partnerships. - **Manufacturing concentration** [high] — IMG-007 active ingredient and drug product are supplied by a single-source manufacturer. - **Strategic alternatives / merger execution** [medium] — Failure or delay in the proposed merger could materially affect results and stock price. - **Competitive pressure** [medium] — Larger biotech and pharma companies may move faster on similar immunology assets. - Clinical failure could eliminate IMG-007's commercial value - Regulatory delays would extend cash burn and delay approval - Single-source manufacturing creates supply and cost risk - Merger failure could hurt valuation and strategic direction - No product sales means ongoing dependence on external capital ## Accounting Revenue is driven by license and collaboration arrangements, so timing depends on contract terms, performance obligations, and milestone recognition rather than product shipments. Investors should watch deferred revenue, upfront payment recognition, and judgment-heavy estimates around R&D accruals and going-concern-style liquidity assumptions in a company that is still pre-commercial. - **ASC 606 revenue recognition for licenses and collaborations** — Can create quarter-to-quarter revenue volatility - **Deferred revenue** — Affects reported revenue timing and balance sheet liabilities - **R&D expense accruals** — Can move operating expense and net loss between periods - **Liquidity and going-concern assumptions** — Important for runway assessment and disclosure risk - License and collaboration revenue timing can be lumpy - Upfront payments may be deferred until obligations are met - Milestone and royalty accounting depends on contract terms - R&D accruals rely on estimates for clinical and vendor costs - No product sales yet, so revenue quality is partnership-driven --- *Last updated: 2026-04-28T20:16:59.677442+00:00*